Current therapies and challenges for the treatment of Staphylococcus aureus biofilm-related infections

Pharmacotherapy. 2023 Aug;43(8):816-832. doi: 10.1002/phar.2806. Epub 2023 May 14.

Abstract

Staphylococcus aureus is a major cause of nosocomial and community-acquired infections and contributes to significant increase in morbidity and mortality especially when associated with medical devices and in biofilm form. Biofilm structure provides a pathway for the enrichment of resistant and persistent phenotypes of S. aureus leading to relapse and recurrence of infection. Minimal diffusion of antibiotics inside biofilm structure leads to heterogeneity and distinct physiological activity. Additionally, horizontal gene transfer between cells in proximity adds to the challenges associated with eradication of biofilms. This narrative review focuses on biofilm-associated infections caused by S. aureus, the impact of environmental conditions on biofilm formation, interactions inside biofilm communities, and the clinical challenges that they present. Conclusively, potential solutions, novel treatment strategies, combination therapies, and reported alternatives are discussed.

Keywords: Staphylococcus aureus; MRSA; biofilm.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Biofilms
  • Community-Acquired Infections* / drug therapy
  • Humans
  • Methicillin-Resistant Staphylococcus aureus* / physiology
  • Microbial Sensitivity Tests
  • Staphylococcal Infections* / drug therapy
  • Staphylococcus aureus

Substances

  • Anti-Bacterial Agents